-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:DOC公佈了2026年第一季業績,其中營收年增率成長7.1%至7.53億美元,租賃收入為7.39億美元(+7.5%),超出市場預期4,600萬美元;儘管每股FFO從0.46美元降至0.45美元,但仍超出預期0.02美元。 Janus Living成功上市,募集資金8.8億美元,打造了一個市值達69億美元的養老地產平台,驗證了管理層的價值釋放策略,而DOC仍持有81.6%的股份。更新後的2026年業績指引反映了IPO的影響,每股收益上調至0.46-0.50美元,而由於管理費收入減少,FFO下調至1.68-1.72美元。同店淨營業收入持平,老年住宅業務的強勁成長(+13.8%)被實驗室業務的疲軟表現(-7.2%)所抵銷。入住率持續承壓,實驗室業務較去年同期下降740個基點至90.4%,門診醫療業務下降70個基點至91.8%。 DOC回購了1億美元的股票。我們認為門診醫療業務的入住率將會改善,但預計實驗室業務的空置率將在2026年第三季之前持續上升。我們認為,生技業務持續面臨的融資挑戰將限制實驗室業務在2027年上半年的成長空間。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.